Key Takeaways
- First-quarter adjusted EPS came in at $0.99, below the analyst estimate of $1.05
- Annual EPS outlook lowered to $4.80–$5.00 from previous range of $4.95–$5.15
- Quarterly revenue reached $5.13 billion, surpassing the $5.03 billion forecast
- Shares declined approximately 9% during premarket hours
- Organizational restructuring creates new $14.6 billion business segment
GE HealthCare delivered disappointing first-quarter results and lowered its annual profit forecast, triggering a steep decline in shares during Wednesday’s premarket session.
The medical technology company reported adjusted earnings of $0.99 per share, falling short of Wall Street’s $1.05 expectation. Revenue performance told a brighter story — the company generated $5.13 billion in quarterly sales, representing 7.4% year-over-year growth and beating the $5.03 billion analyst consensus.
Operating margins reached 13.5%, approximately one percentage point below projections.
Premarket trading saw the stock decline roughly 9.6% to around $61.93 per share, compounding an already challenging year. Shares had declined 16% year-to-date through Tuesday’s close.
GE HealthCare Technologies Inc., GEHC
Chief Executive Peter Arduini attributed the reduced guidance to escalating cost pressures. The company experienced higher prices for memory chips, petroleum products, and shipping services throughout the quarter. Arduini indicated that GE HealthCare anticipates offsetting over half of these inflationary impacts through strategic pricing adjustments and cost management initiatives.
The revised full-year adjusted earnings outlook now stands at $4.80–$5.00 per share, down from the previous projection of $4.95–$5.15. The consensus analyst estimate had been $5.06. Management maintained its organic revenue growth target of 3% to 4%.
First-quarter orders increased 1.1%, while comparable revenue expanded 2.9%.
Major Organizational Overhaul
GE HealthCare revealed plans to merge its two primary divisions — imaging and advanced visualization solutions — creating a unified segment named Advanced Imaging Solutions, representing a $14.6 billion revenue platform.
Phil Rackliffe, who previously oversaw advanced visualization solutions, will assume leadership of the consolidated division. Roland Rott, the former imaging segment head, is departing the organization.
Management characterized the reorganization as a strategic initiative to build a more integrated imaging platform and drive operational efficiencies.
Catherine Estrampes, a 35-year company veteran, received an appointment as Chief Commercial and Growth Officer, leading a newly established global markets division responsible for all territories excluding China.
Underperforming Fellow GE Spinoffs
GEHC has struggled compared to the other two entities emerging from the legacy General Electric conglomerate. Following its January 2023 separation, shares have gained merely 13%, underperforming the S&P 500 by over 70 percentage points during this timeframe.
Meanwhile, GE Aerospace has surged more than 110% since GE’s division in April 2024. GE Vernova has been the exceptional performer, skyrocketing over 675% during the identical period.
GE Aerospace has capitalized on robust aircraft engine demand. GE Vernova has benefited from substantial power infrastructure investment. GE HealthCare has navigated a more challenging landscape — soft demand conditions, tariff uncertainties, and ongoing inflationary pressures.
The company maintains a record order backlog approaching $22 billion as it entered 2026, which leadership has highlighted as a platform for sustained expansion.
GEHC shares had advanced just 1% during the trailing twelve months prior to Wednesday’s earnings announcement.
